Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Icu Medical (ICUI) Cash & Equivalents (2016 - 2025)

Icu Medical (ICUI) has disclosed Cash & Equivalents for 17 consecutive years, with $308.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents changed 0.2% year-over-year to $308.0 million, compared with a TTM value of $308.0 million through Dec 2025, changed 0.2%, and an annual FY2025 reading of $308.0 million, changed 0.2% over the prior year.
  • Cash & Equivalents was $308.0 million for Q4 2025 at Icu Medical, up from $299.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $552.8 million in Q4 2021 and bottomed at $195.9 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $313.0 million, with a median of $300.0 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents tumbled 62.23% in 2022, then skyrocketed 58.48% in 2024.
  • Year by year, Cash & Equivalents stood at $552.8 million in 2021, then crashed by 62.23% to $208.8 million in 2022, then increased by 21.76% to $254.2 million in 2023, then grew by 21.38% to $308.6 million in 2024, then decreased by 0.2% to $308.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for ICUI at $308.0 million in Q4 2025, $299.7 million in Q3 2025, and $300.0 million in Q2 2025.